Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 4, Pages 887-895Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.935366
Keywords
AVIDA; azacitidine; myelodysplastic syndromes; lower-risk MDS
Categories
Funding
- Celgene Corporation
Ask authors/readers for more resources
The AVIDA registry evaluated azacitidine usage and effectiveness in unselected patients with myelodysplastic syndromes (MDS) in community practice. Treating physicians made all treatment decisions. Hematologic improvement (HI) and transfusion independence (TI) assessments used International Working Group (IWG) 2000 criteria. Enrolled were 421 patients with MDS (n = 228 International Prognostic Scoring System [IPSS] lower-risk, n = 106 higher-risk, 86 patients unclassified) from 105 US sites. Median follow-up was 7.6 months (range: 0.1-27.6). HI and red blood cell TI rates were similar regardless of administration route or dosing schedule. Safety and tolerability were consistent with previous reports. The AVIDA registry data support azacitidine effectiveness and safety in patients with lower- or higher-risk MDS treated in community practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available